Rafael Dal-Ré

Rafael Dal-Ré

Auto-generated profile, based on publicly available information

Rafael Dal-Ré

Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2014 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
RDRafael Dal-Ré
Rafael Dal-Ré
JIJohn P. Ioannidis
John P. Ioannidis
MBMichael B. Bracken
Michael B. Bracken
PBPatricia A. Buffler
Patricia A. Buffler
ACAn-Wen Chan
An-Wen Chan
EWElisabete Weiderpass
Elisabete Weiderpass
Key information about human observational studies should be publicly available before the study is initiated.

23 August 2018 in Trials
Verified
Journal Article
Open access
PDF file
AGAnand D. Gopal
Anand D. Gopal
JWJoshua D. Wallach
Joshua D. Wallach
JAJenerius A. Aminawung
Jenerius A. Aminawung
GGGregg Gonsalves
Gregg Gonsalves
RDRafael Dal-Ré
Rafael Dal-Ré
JRJoseph S. Ross
Joseph S. Ross
Registration of clinical trials is critical for promoting transparency and integrity in medical research; however, trials must be registered in a prospective fashion to deter unaccounted protocol modifications or selection of alternate outcomes that may enhance favorability of reported findings. We assessed adherence to the International Committee of Medical Journal Editors’ (ICMJE) prospective registration policy and identified the frequency of registrations occurring after potential observation of primary outcome data among trials published in the highest-impact journals associated with US professional medical societies. Additionally, we examined whether trials that are unregistered or registered after potential observation of primary outcome data were more likely to report favorable findings. We conducted a retrospective, cross-sectional analysis of the 50 most recently published clinical trials that reported primary results in each of the ten highest-impact US medical specialty society journals between 1 January 2010 and 31 December 2015. We used descriptive statistics to characterize the proportions of trials that were: registered; registered retrospectively; registered retrospectively potentially after initial ascertainment of primary outcomes; and reporting favorable findings, overall and stratified by journal and trial characteristics. Chi-squared analyses were performed to assess differences in registration by journal and trial characteristics. We reviewed 6869 original research reports published between 1 January 2010 and 31 December 2015 to identify a total of 486 trials across 472 publications. Of these 486 trials, 47 (10%) were unregistered. Among 439 registered trials, 340 (77%) were registered prospectively and 99 (23%) retrospectively. Sixty-seven (68%) of these 99 retrospectively registered trials, or 15% of all 439 registered trials, were registered after potential observation of primary outcome data ascertained among participants enrolled at inception. Industry-funded trials, those with enrollment sites in the US, as well as those assessing FDA-regulated interventions each had lower rates of retrospective registration. Unregistered trials were more likely to report favorable findings than were registered trials (89% vs. 64%; relative risk (RR) = 1.38, 95% confidence interval (CI) = 1.20–1.58; p = 0.004), irrespective of registration timing. Adherence to the ICMJE’s prospective registration policy remains sub-standard, even in the highest-impact journals associated with US professional medical societies. These journals frequently published unregistered trials and trials registered after potential observation of primary outcome data.

16 January 2020 in Research Ethics
Verified
Journal Article
Open access
PDF file
RDRafael Dal-Ré
Rafael Dal-Ré
LBLex M Bouter
Lex M Bouter
PCPim Cuijpers
Pim Cuijpers
CGChristian Gluud
Christian Gluud
SHSøren Holm
Søren Holm
For more than 25 years, research misconduct (research fraud) is defined as fabrication, falsification, or plagiarism (FFP)—although other research misbehaviors have been also added in codes of conduct and legislations. A critical issue in deciding whether research misconduct should be subject to criminal law is its definition, because not all behaviors labeled as research misconduct qualifies as serious crime. But assuming that all FFP is fraud and all non-FFP not is far from obvious. In addition, new research misbehaviors have recently been described, such as prolific authorship, and fake peer review, or boosted such as duplication of images. The scientific community has been largely successful in keeping criminal law away from the cases of research misconduct. Alleged cases of research misconduct are usually looked into by committees of scientists usually from the same institution or university of the suspected offender in a process that often lacks transparency. Few countries have or plan to introduce independent bodies to address research misconduct; so for the coming years, most universities and research institutions will continue handling alleged research misconduct cases with their own procedures. A global operationalization of research misconduct with clear boundaries and clear criteria would be helpful. There is room for improvement in reaching global clarity on what research misconduct is, how allegations should be handled, and which sanctions are appropriate.

29 March 2022 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
RDRafael Dal-Ré
Rafael Dal-Ré
SBSören L Becker
Sören L Becker
EBEmmanuel Bottieau
Emmanuel Bottieau
SHSøren Holm
Søren Holm

27 March 2015 in BMJ
Verified
Journal Article
Closed access
PDF file
RDRafael Dal-Ré
Rafael Dal-Ré
MBMichael B Bracken
Michael B Bracken
JIJ. P. A. Ioannidis
J. P. A. Ioannidis
The public and clinicians require transparent, quality evidence for all interventions. Trials of non-regulated interventions are common, and efforts to improve their registration and publication compared with drug trials are overdue, say Rafael Dal-Ré, Michael Bracken, and John Ioannidis